Mechanism of Action: The Unique Pattern of Bendamustine-Induced Cytotoxicity

Seminars in Hematology

Volumn 48, Issue SUPPL. 1, 2011, Pages

  Leoni, Lorenzo M ^a   Hartley, John A ^b  

^a Actus Advisory   (Switzerland)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENDAMUSTINE; CARBOPLATIN; CARMUSTINE; CASPASE 2; CASPASE 3; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA; EXONUCLEASE; FLUDARABINE; GEFITINIB; GEMCITABINE; MELPHALAN; PHOSPHORAMIDE MUSTARD; PROTEIN BCL 2; PROTEIN P53; SJG 136; TREOSULFAN; UNCLASSIFIED DRUG;

ALKYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RECURRENCE; CELL CYCLE ARREST; CELL CYCLE REGULATION; CELL PROLIFERATION; DNA CROSS LINKING; DNA DAMAGE; DNA METABOLISM; DNA REPAIR; DNA REPLICATION; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; EXCISION REPAIR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; MISMATCH REPAIR; MULTIPLE MYELOMA; OVARY CANCER; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; UPREGULATION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; DNA; DNA DAMAGE; HEMATOLOGIC NEOPLASMS; HUMANS; NITROGEN MUSTARD COMPOUNDS;

EID: 79955365952     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2011.03.003     Document Type: Article

References (82)

1. Cheson B.D., Rummel M.J. Bendamustine: rebirth of an old drug. J Clin Oncol 2009, 27:1492-1501.
2. Kalaycio M. Bendamustine: a new look at an old drug. Cancer 2009, 115:473-479.
3. O'Connor P.M., Kohn K.W. Comparative pharmacokinetics of DNA lesion formation and removal following treatment of L1210 cells with nitrogen mustards. Cancer Commun 1990, 2:387-394.
4. McHugh P.J., Spanswick V.J., Hartley J.A. Repair of DNA interstrand crosslinks: molecular mechanisms and clinical relevance. Lancet Oncol 2001, 2:483-490.
5. Spanswick V.J., Craddock C., Sekhar M., et al. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood 2002, 100:224-229.
6. Torres-Garcia S.J., Cousineau L., Caplan S., Panasci L. Correlation of resistance to nitrogen mustards in chronic lymphocytic leukemia with enhanced removal of melphalan-induced DNA cross-links. Biochem Pharmacol 1989, 38:3122-3123.
7. Leoni L.M., Bailey B., Reifert J., et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 2008, 14:309-317.
8. Roue G., Lopez-Guerra M., Milpied P., et al. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling. Clin Cancer Res 2008, 14:6907-6915.
9. Lindahl T., Satoh M.S., Poirier G.G., Klungland A. Post-translational modification of poly(ADP-ribose) polymerase induced by DNA strand breaks. Trends Biochem Sci 1995, 20:405-411.
10. Soldani C., Scovassi A.I. Poly(ADP-ribose) polymerase-1 cleavage during apoptosis: an update. Apoptosis 2002, 7:321-328.
11. Boulares A.H., Yakovlev A.G., Ivanova V., et al. Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem 1999, 274:22932-22940.
12. ™) in non-Hodgkin's lymphoma cells. Presented at Pan-Pacific Lymphoma Conference; July 11-15, 2005; Kauai, Hawaii.
13. Knauf W.U., Lissichkov T., Aldaoud A., et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009, 27:4378-4384.
14. Casenghi M., Meraldi P., Weinhart U., Duncan P.I., Korner R., Nigg E.A. Polo-like kinase 1 regulates Nlp, a centrosome protein involved in microtubule nucleation. Dev Cell 2003, 5:113-125.
15. Hirota T., Kunitoku N., Sasayama T., et al. Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells. Cell 2003, 114:585-598.
16. Castedo M., Perfettini J.L., Roumier T., Andreau K., Medema R., Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 2004, 23:2825-2837.
17. Castedo M., Perfettini J.L., Roumier T., et al. Mitotic catastrophe constitutes a special case of apoptosis whose suppression entails aneuploidy. Oncogene 2004, 23:4362-4370.
18. Chow K.U., Boehrer S., Geduldig K., et al. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica 2001, 86:485-493.
19. Chow K.U., Nowak D., Boehrer S., et al. Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation. Biochem Pharmacol 2003, 66:711-724.
20. De Silva I.U., McHugh P.J., Clingen P.H., Hartley J.A. Defining the roles of nucleotide excision repair and recombination in the repair of DNA interstrand cross-links in mammalian cells. Mol Cell Biol 2000, 20:7980-7990.
21. Schwanen C., Hecker T., Hubinger G., et al. In vitro evaluation of bendamustine induced apoptosis in B-chronic lymphocytic leukemia. Leukemia 2002, 16:2096-2105.
22. Gandhi V. Metabolism and mechanisms of action of bendamustine: rationales for combination therapies. Semin Oncol 2002, 29(Suppl 13):4-11.
23. Hartley J.A. Alkylating agents. Oxford textbook of oncology 2001, 639-654. Oxford University Press, Oxford. 2nd ed. R.L. Souhami, I.F. Tannock, P. Hohenberger, J.-C. Horiot (Eds.).
24. Hartley J.A., Gibson N.W., Kohn K.W., Mattes W.B. DNA sequence selectivity of guanine-N7 alkylation by three antitumor chloroethylating agents. Cancer Res 1986, 46:1943-1947.
25. Mattes W.B., Hartley J.A., Kohn K.W. DNA sequence selectivity of guanine-N7 alkylation by nitrogen mustards. Nucleic Acids Res 1986, 14:2971-2987.
26. Kohn K.W., Hartley J.A., Mattes W.B. Mechanisms of DNA sequence selective alkylation of guanine-N7 positions by nitrogen mustards. Nucleic Acids Res 1987, 15:10531-10549.
27. Hartley J.A., Bingham J.P., Souhami R.L. DNA sequence selectivity of guanine-N7 alkylation by nitrogen mustards is preserved in intact cells. Nucleic Acids Res 1992, 20:3175-3178.
28. Broggini M., Coley H.M., Mongelli N., et al. DNA sequence-specific adenine alkylation by the novel antitumor drug tallimustine (FCE 24517), a benzoyl nitrogen mustard derivative of distamycin. Nucleic Acids Res 1995, 23:81-87.
29. Wyatt M.D., Lee M., Garbiras B.J., Souhami R.L., Hartley J.A. Sequence specificity of alkylation for a series of nitrogen mustard-containing analogues of distamycin of increasing binding site size: evidence for increased cytotoxicity with enhanced sequence specificity. Biochemistry 1995, 34:13034-13041.
30. Pieper R.O., Erickson L.C. DNA adenine adducts induced by nitrogen mustards and their role in transcription termination in vitro. Carcinogenesis 1990, 11:1739-1746.
31. Hartley J.A., Wyatt M.D. Determination of the sequence specificity of alkylation damage using cleavage-based assays. Methods in molecular biology. Vol 90: Drug-DNA interaction protocols 1997, 147-156. Humana Press, Totowa, NJ. K. Fox (Ed.).
32. Ponti M., Forrow S.M., Souhami R.L., D'Incalci M., Hartley J.A. Measurement of the sequence specificity of covalent DNA modification by antineoplastic agents using Taq DNA polymerase. Nucleic Acids Res 1991, 19:2929-2933.
33. Grimaldi K.A., McGurk C.J., McHugh P.J., Hartley J.A. PCR-based methods for detecting DNA damage and its repair at the sub-gene and single nucleotide levels in cells. Mol Biotechnol 2002, 20:181-196.
34. McGurk C.J., McHugh P.J., Tilby M.J., Grimaldi K.A., Hartley J.A. Measurement of covalent drug-DNA interactions at the nucleotide level in cells at pharmacologically relevant doses. Methods Enzymol 2001, 340:358-376.
35. Colvin O.M., Friedman H.S., Gamcsik M.P., Fenselau C., Hilton J. Role of glutathione in cellular resistance to alkylating agents. Adv Enzyme Regul 1993, 33:19-26.
36. Strumberg D., Harstrick A., Doll K., Hoffmann B., Seeber S. Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 1996, 7:415-421.
37. Sunters A., Springer C.J., Bagshawe K.D., Souhami R.L., Hartley J.A. The cytotoxicity, DNA crosslinking ability and DNA sequence selectivity of the aniline mustards melphalan, chlorambucil and 4-[bis(2-chloroethyl)amino] benzoic acid. Biochem Pharmacol 1992, 44:59-64.
38. Lawley P.D., Phillips D.H. DNA adducts from chemotherapeutic agents. Mutat Res 1996, 355:13-40.
39. Brendel M., Ruhland A. Relationships between functionality and genetic toxicology of selected DNA-damaging agents. Mutat Res 1984, 133:51-85.
40. Hartmann M., Zimmer C. Investigation of cross-link formation in DNA by the alkylating cytostatic IMET 3106, 3393 and 3943. Biochim Biophys Acta 1972, 287:386-389.
41. Kohn K.W., Ewig R.A.G., Erickson L.C., Zwelling L.A. Measurement of strand breaks and crosslinks by alkyline elution. DNA repair 1981, 379-408. Dekker, New York. E.C. Friedberg, P.C. Hanawalt (Eds.).
42. Spanswick V.J., Hartley J.M., Hartley J.A. Measurement of DNA interstrand crosslinking in individual cells using the single cell gel electrophoresis (comet) assay. Methods in molecular biology. Vol 613: Drug-DNA interaction protocols 2010, 267-282. Humana Press, Totowa, NJ. 2nd ed. K. Fox (Ed.).
43. Hartley J.M., Spanswick V.J., Gander M., et al. Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (comet) assay. Clin Cancer Res 1999, 5:507-512.
44. Clingen P.H., De Silva I.U., McHugh P.J., et al. The XPF-ERCC1 endonuclease and homologous recombination contribute to the repair of minor groove DNA interstrand crosslinks in mammalian cells produced by the pyrrolo[2,1-c][1,4]benzodiazepine dimer SJG-136. Nucleic Acids Res 2005, 33:3283-3291.
45. McHugh P.J., Sones W.R., Hartley J.A. Repair of intermediate structures produced at DNA interstrand cross-links in Saccharomyces cerevisiae. Mol Cell Biol 2000, 20:3425-3433.
46. De Silva I.U., McHugh P.J., Clingen P.H., Hartley J.A. Defects in interstrand cross-link uncoupling do not account for the extreme sensitivity of ERCC1 and XPF cells to cisplatin. Nucleic Acids Res 2002, 30:3848-3856.
47. McHugh P.J., Gill R.D., Waters R., Hartley J.A. Excision repair of nitrogen mustard-DNA adducts in Saccharomyces cerevisiae. Nucleic Acids Res 1999, 27:3259-3266.
48. Yan T., Seo Y., Schupp J.E., Zeng X., Desai A.B., Kinsella T.J. Methoxyamine potentiates iododeoxyuridine-induced radiosensitization by altering cell cycle kinetics and enhancing senescence. Mol Cancer Ther 2006, 5:893-902.
49. Kinsella T.J. Coordination of DNA mismatch repair and base excision repair processing of chemotherapy and radiation damage for targeting resistant cancers. Clin Cancer Res 2009, 15:1853-1859.
50. Tran P.T., Erdeniz N., Symington L.S., Liskay R.M. EXO1-A multi-tasking eukaryotic nuclease. DNA Repair (Amst) 2004, 3:1549-1559.
51. Cai Y., Ludeman S.M., Wilson L.R., Chung A.B., Dolan M.E. Effect of O6-benzylguanine on nitrogen mustard-induced toxicity, apoptosis, and mutagenicity in Chinese hamster ovary cells. Mol Cancer Ther 2001, 1:21-28.
52. McCabe K.M., Olson S.B., Moses R.E. DNA interstrand crosslink repair in mammalian cells. J Cell Physiol 2009, 220:569-573.
53. Wynne P., Newton C., Ledermann J.A., Olaitan A., Mould T.A., Hartley J.A. Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy. Br J Cancer 2007, 97:927-933.
54. Köberle B., Masters J.R., Hartley J.A., Wood R.D. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 1999, 9:273-276.
55. Knop S., Straka C., Haen M., Schwedes R., Hebart H., Einsele H. The efficacy and toxicity of bendamustine in recurrent multiple myeloma after high-dose chemotherapy. Haematologica 2005, 90:1287-1288.
56. Pönisch W., Mitrou P.S., Merkle K., et al. Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone-a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). J Cancer Res Clin Oncol 2006, 132:205-212.
57. Bergman A.M., Ruiz van Haperen V.W., Veerman G., Kuiper C.M., Peters G.J. Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996, 2:521-530.
58. Ledermann J.A., Gabra H., Jayson G.C., et al. Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer. Clin Cancer Res 2010, 16:4899-4905.
59. Corrie P.G., Shaw J., Spanswick V.J., et al. Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients. Br J Cancer 2005, 92:1997-2003.
60. Li L., Keating M.J., Plunkett W., Yang L.Y. Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance. Mol Pharmacol 1997, 52:798-806.
61. Moufarij M.A., Sampath D., Keating M.J., Plunkett W. Fludarabine increases oxaliplatin cytotoxicity in normal and chronic lymphocytic leukemia lymphocytes by suppressing interstrand DNA crosslink removal. Blood 2006, 108:4187-4193.
62. Pepper C., Lowe H., Fegan C., et al. Fludarabine-mediated suppression of the excision repair enzyme ERCC1 contributes to the cytotoxic synergy with the DNA minor groove crosslinking agent SJG-136 (NSC 694501) in chronic lymphocytic leukaemia cells. Br J Cancer 2007, 97:253-259.
63. Friedmann B., Caplin M., Hartley J.A., Hochhauser D. Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839). Clin Cancer Res 2004, 10:6476-6486.
64. Boone J.J., Bhosle J., Tilby M.J., Hartley J.A., Hochhauser D. Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents. Mol Cancer Ther 2009, 8:3015-3023.
65. Mukhopadhyay A., Elattar A., Cerbinskaite A., et al. Development of a functional assay for homologous recombination status in primary cultures of epithelial ovarian tumor and correlation with sensitivity to poly(ADP-ribose) polymerase inhibitors. Clin Cancer Res 2010, 16:2344-2351.
66. Drew Y., Mulligan E.A., Vong W.T., et al. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst 2011, 103:334-346.
67. Fillingham J., Keogh M.C., Krogan N.J. γH2AX and its role in DNA double-strand break repair. Biochem Cell Biol 2006, 84:568-577.
68. Paull T.T., Rogakou E.P., Yamazaki V., Kirchgessner C.U., Gellert M., Bonner W.M. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Biol 2000, 10:886-895.
69. Furuta T., Takemura H., Liao Z.Y., et al. Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes. J Biol Chem 2003, 278:20303-20312.
70. Dickey J.S., Redon C.E., Nakamura A.J., Baird B.J., Sedelnikova O.A., Bonner W.M. H2AX: functional roles and potential applications. Chromosoma 2009, 118:683-692.
71. Redon C.E., Nakamura A.J., Zhang Y.W., et al. Histone gammaH2AX and poly(ADP-ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res 2010, 16:4532-4542.
72. Banuelos C.A., Banath J.P., Kim J.Y., Aquino-Parsons C., Olive P.L. γH2AX expression in tumors exposed to cisplatin and fractionated irradiation. Clin Cancer Res 2009, 15:3344-3353.
73. Clingen P.H., Wu J.Y., Miller J., et al. Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy. Biochem Pharmacol 2008, 76:19-27.
74. Hochhauser D., Meyer T., Spanswick V.J., et al. Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors. Clin Cancer Res 2009, 15:2140-2147.
75. Smith J., Tho L.M., Xu N., Gillespie D.A. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 2010, 108:73-112.
76. Kobayashi J., Antoccia A., Tauchi H., Matsuura S., Komatsu K. NBS1 and its functional role in the DNA damage response. DNA Repair (Amst) 2004, 3:855-861.
77. Pichierri P., Averbeck D., Rosselli F. DNA cross-link-dependent RAD50/MRE11/NBS1 subnuclear assembly requires the Fanconi anemia C protein. Hum Mol Genet 2002, 11:2531-2546.
78. Gaul L., Mandl-Weber S., Baumann P., Emmerich B., Schmidmaier R. Bendamustine induces G2 cell cycle arrest and apoptosis in myeloma cells: the role of ATM-Chk2-Cdc25A and ATM-p53-p21-pathways. J Cancer Res Clin Oncol 2008, 134:245-253.
79. Dai Y., Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res 2010, 16:376-383.
80. Konstantinov S.M., Kostovski A., Topashka-Ancheva M., Genova M., Berger M.R. Cytotoxic efficacy of bendamustine in human leukemia and breast cancer cell lines. J Cancer Res Clin Oncol 2002, 128:271-278.
81. Staib P., Schinkohe T., Dimski T. In vitro modulation of Ara-CTP accumulation in fresh AML cells by bendamustine in comparison with fludarabine, 2-CDA and gemcitabine. Blood 1999, 94.
82. Leoni L.M., Niemeyer C.C., Kerfoot C. In vitro and ex vivo activity of SDX-105 (bendamustine) in drug-resistant lymphoma cells. Proc Am Assoc Cancer Res 2004, 45:278. [abstract 1215].